Thus, BMP9 was shown to serve as a potential biomarker and therapeutic target in MASLD and metabolic syndromes (Xu et al., 2017; Li et al., 2018; Chen et al., 2024; Yang et al., 2024). The gene discussed is GDF2; the disease is metabolic dysfunction-associated steatotic liver disease.